Aurion Biotechnologies
Seattle
About Aurion Biotechnologies
Based in Seattle, Boston and Tokyo, Aurion Biotech is a clinical-stage biotech company. Our mission is to cure leading forms of blindness and transform the lives of millions of patients, by developing a platform of advanced therapies to treat ocular diseases. Our first candidate is for the treatment of corneal edema, and one of the first clinically validated cell therapies for corneal care. Healthy cells from a donor cornea are cultured in a novel, multi-step, proprietary and patented process. Cells from a single donor can be used to treat more than 100 recipient eyes. In clinical trials in Japan, patients have experienced significant and durable improvements in key measures of corneal health: visual acuity, corneal endothelial cell density and corneal thickness.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $120.0M
- Funding stage: M&A
- Last round: Series Unknown (Apr 2022)
- Website: aurionbiotech.com
- Phone: +1 4159712900
Industries & Categories
Biopharma, Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/aurion-biotechnologies-37153 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.